Popular Boards

Key Takeaways

Plain English Takeaway

How well a special type of starch helps with a common liver disease depends on the unique mix of bacteria in each person's gut.

Study Aim

The study aims to find out why resistant starch (a type of fiber that resists digestion) works better for some people than others in treating metabolic dysfunction-associated steatotic liver disease (MASLD, a liver condition linked to metabolism problems). The researchers want to see if differences in gut microbiome (the community of bacteria living in the intestines) explain this variation. Simply put: The study wants to know if gut bacteria differences explain why a certain fiber helps some people with liver disease more than others.

Study Design

The researchers conducted a study where they gave resistant starch to people with MASLD. They collected samples from the participants to analyze their gut microbiome before and after the treatment. The team compared how each person's gut bacteria changed and how these changes related to improvements in their liver condition. They looked for patterns that could explain why some people responded better to the resistant starch than others. Simply put: The study gave a special fiber to people with liver disease and checked if changes in their gut bacteria matched how much their health improved.

Findings

The study reveals that the effectiveness of resistant starch in improving MASLD varies from person to person, and this difference is linked to the unique makeup of each individual's gut microbiome. The authors demonstrate that certain gut bacteria are associated with better responses to the treatment. This suggests that targeting the gut microbiome could help create more personalized treatments for MASLD in the future. The research recommends considering a person's gut bacteria when deciding on resistant starch therapy for liver disease. Simply put: The study found that the mix of gut bacteria helps decide how well a special fiber works for people with liver disease, so treatments could be more personal in the future.

Abstract

No abstract available

Referenced In

[Physionic] Resistant Starch is OP?

www.youtube.comI watched this great video from Physionic on the scientific literature on resistant starch and its impact on visceral fat and liver health. Very compelling evidence via placebo controlled RCTs on resistant starch's ability to treat Metabolic dysfunction-associated steatotic liver disease (MASLD) or fka NAFLD and weight loss plus 6 more studies as provided by Physionic. He states that compared to placebo, the studies show 300% relative or 20% absolute improvement in reducing visceral fat.

Visceral fat, the fat that surrounds internal organs, can put people at higher risk for several diseases like cardiovascular disease and specifically contributes to fatty liver disease, even when compared to other fat types.

The most common type of resistant starch (RS3) is formed when the starch in foods like rice, pasta, and potatoes is cooked and then cooled allowing the starch to crystallize in a process called retrogradation. The starch becomes undigestible for humans but becomes fuel for our gut microbiome. Raw starch (RS2) found in potato starch, green bananas, or high-amylose maize acts similarly and is most commonly used in supplements.

The theoretical biological mechanism for this improvement is via the reduction of a harmful bacteria that is crowded out by other bacteria that thrive on resistant starch. Even more interesting, Physionic found that 70% are hyper-responders to resistant starch.

Resistant starch, because indigestible, packs significantly less caloric and carbohydrate punch than its non-resistant version. But these studies show that it goes beyond harm reduction. Resistant starch can have positive effects especially with supplementation to reach minimum effective doses.

6